Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5628643 | Epilepsy Research | 2017 | 9 Pages |
Abstract
Based on level 2 evidence, RS is an efficacious treatment to control seizures in MTLE, possibly resulting in superior neuropsychological outcomes and quality of life metrics in selected subjects compared to microsurgery. RS has a better risk-benefit ratio for small hypothalamic hamartomas compared to surgical methods Delayed therapeutic effect resulting in ongoing seizures is associated with morbidity and mortality risk. Lack of level 1 evidence precludes the formation of guidelines at present.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Aileen McGonigal, Arjun Sahgal, Antonio De Salles, Motohiro Hayashi, Marc Levivier, Lijun Ma, Roberto Martinez, Ian Paddick, Samuel Ryu, Ben J. Slotman, Jean Régis,